# Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV

> **NCT02032901** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 173 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Daclatasvir
- **DRUG:** Sofosbuvir

## Key facts

- **NCT ID:** NCT02032901
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-09
- **Final completion:** 2014-12
- **Target enrollment:** 173 (ACTUAL)
- **Last updated:** 2015-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02032901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02032901, "Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02032901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*